Life expectancy after implantation of a first cardiac permanent pacemaker (1995-2008): A population-based study

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

© 2015 Published by Elsevier Ireland Ltd. Introduction: Research suggests that survival among the recipients of a cardiac permanent pacemaker (PPM) matches the age- and sex-matched general population in the absence of cardiovascular disease. We used linked administrative data to examine life expectancy-based outcomes for adults requiring a cardiac PPM. Methods: Population-level hospital admissions data were used to identify all recipients of an initial PPM during 1995-2008. Expected years of additional life remaining at the time of implantation were calculated for each patient from population life tables. Observed years were calculated using linked mortality data to end 2011. Cox regression was used to determine demographic and clinical predictors of survival. Results: In 8757 patients age-adjusted risk of death to 5 years was associated with male sex, higher Charlson Comorbidity Index score (excluding cardiac disease), a history of heart failure, cardiomyopathy or atrial fibrillation and emergency admission. Coronary revascularisation surgery reduced long-term risk. The observed/expected ratio of additional years of life was 0.80 for men and 0.84 for women overall, varying from 0.92 for women without significant comorbidity to 0.40 for patients with the highest Charlson score and cardiomyopathy. The oldest patients (80-99 years) did relatively well, probably reflecting patient selection. Heart disease was the most frequent cause of death. Conclusions: Life expectancy among PPMrecipientswithout significant comorbidity approached that of the general population. Greater non-cardiac comorbidity, heart failure, atrial fibrillation and, in particular, cardiomyopathy, contributedmost to the loss of expected years of life in all age groups. The oldest patients andwomen did relatively well.
Original languageEnglish
Pages (from-to)42-46
JournalInternational Journal of Cardiology
Volume190
Issue number1
DOIs
Publication statusPublished - 2015

Fingerprint

Life Expectancy
Comorbidity
Cardiomyopathies
Population
Atrial Fibrillation
Heart Diseases
Heart Failure
Life Tables
Survival
Ireland
Patient Selection
Cause of Death
Emergencies
Cardiovascular Diseases
Age Groups
Demography
Mortality
Research

Cite this

@article{62489782da00436e8c98c2e7b7fe2450,
title = "Life expectancy after implantation of a first cardiac permanent pacemaker (1995-2008): A population-based study",
abstract = "{\circledC} 2015 Published by Elsevier Ireland Ltd. Introduction: Research suggests that survival among the recipients of a cardiac permanent pacemaker (PPM) matches the age- and sex-matched general population in the absence of cardiovascular disease. We used linked administrative data to examine life expectancy-based outcomes for adults requiring a cardiac PPM. Methods: Population-level hospital admissions data were used to identify all recipients of an initial PPM during 1995-2008. Expected years of additional life remaining at the time of implantation were calculated for each patient from population life tables. Observed years were calculated using linked mortality data to end 2011. Cox regression was used to determine demographic and clinical predictors of survival. Results: In 8757 patients age-adjusted risk of death to 5 years was associated with male sex, higher Charlson Comorbidity Index score (excluding cardiac disease), a history of heart failure, cardiomyopathy or atrial fibrillation and emergency admission. Coronary revascularisation surgery reduced long-term risk. The observed/expected ratio of additional years of life was 0.80 for men and 0.84 for women overall, varying from 0.92 for women without significant comorbidity to 0.40 for patients with the highest Charlson score and cardiomyopathy. The oldest patients (80-99 years) did relatively well, probably reflecting patient selection. Heart disease was the most frequent cause of death. Conclusions: Life expectancy among PPMrecipientswithout significant comorbidity approached that of the general population. Greater non-cardiac comorbidity, heart failure, atrial fibrillation and, in particular, cardiomyopathy, contributedmost to the loss of expected years of life in all age groups. The oldest patients andwomen did relatively well.",
author = "Pamela Bradshaw and P. Stobie and Matthew Knuiman and Tom Briffa and Michael Hobbs",
year = "2015",
doi = "10.1016/j.ijcard.2015.04.099",
language = "English",
volume = "190",
pages = "42--46",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Life expectancy after implantation of a first cardiac permanent pacemaker (1995-2008): A population-based study

AU - Bradshaw, Pamela

AU - Stobie, P.

AU - Knuiman, Matthew

AU - Briffa, Tom

AU - Hobbs, Michael

PY - 2015

Y1 - 2015

N2 - © 2015 Published by Elsevier Ireland Ltd. Introduction: Research suggests that survival among the recipients of a cardiac permanent pacemaker (PPM) matches the age- and sex-matched general population in the absence of cardiovascular disease. We used linked administrative data to examine life expectancy-based outcomes for adults requiring a cardiac PPM. Methods: Population-level hospital admissions data were used to identify all recipients of an initial PPM during 1995-2008. Expected years of additional life remaining at the time of implantation were calculated for each patient from population life tables. Observed years were calculated using linked mortality data to end 2011. Cox regression was used to determine demographic and clinical predictors of survival. Results: In 8757 patients age-adjusted risk of death to 5 years was associated with male sex, higher Charlson Comorbidity Index score (excluding cardiac disease), a history of heart failure, cardiomyopathy or atrial fibrillation and emergency admission. Coronary revascularisation surgery reduced long-term risk. The observed/expected ratio of additional years of life was 0.80 for men and 0.84 for women overall, varying from 0.92 for women without significant comorbidity to 0.40 for patients with the highest Charlson score and cardiomyopathy. The oldest patients (80-99 years) did relatively well, probably reflecting patient selection. Heart disease was the most frequent cause of death. Conclusions: Life expectancy among PPMrecipientswithout significant comorbidity approached that of the general population. Greater non-cardiac comorbidity, heart failure, atrial fibrillation and, in particular, cardiomyopathy, contributedmost to the loss of expected years of life in all age groups. The oldest patients andwomen did relatively well.

AB - © 2015 Published by Elsevier Ireland Ltd. Introduction: Research suggests that survival among the recipients of a cardiac permanent pacemaker (PPM) matches the age- and sex-matched general population in the absence of cardiovascular disease. We used linked administrative data to examine life expectancy-based outcomes for adults requiring a cardiac PPM. Methods: Population-level hospital admissions data were used to identify all recipients of an initial PPM during 1995-2008. Expected years of additional life remaining at the time of implantation were calculated for each patient from population life tables. Observed years were calculated using linked mortality data to end 2011. Cox regression was used to determine demographic and clinical predictors of survival. Results: In 8757 patients age-adjusted risk of death to 5 years was associated with male sex, higher Charlson Comorbidity Index score (excluding cardiac disease), a history of heart failure, cardiomyopathy or atrial fibrillation and emergency admission. Coronary revascularisation surgery reduced long-term risk. The observed/expected ratio of additional years of life was 0.80 for men and 0.84 for women overall, varying from 0.92 for women without significant comorbidity to 0.40 for patients with the highest Charlson score and cardiomyopathy. The oldest patients (80-99 years) did relatively well, probably reflecting patient selection. Heart disease was the most frequent cause of death. Conclusions: Life expectancy among PPMrecipientswithout significant comorbidity approached that of the general population. Greater non-cardiac comorbidity, heart failure, atrial fibrillation and, in particular, cardiomyopathy, contributedmost to the loss of expected years of life in all age groups. The oldest patients andwomen did relatively well.

U2 - 10.1016/j.ijcard.2015.04.099

DO - 10.1016/j.ijcard.2015.04.099

M3 - Article

VL - 190

SP - 42

EP - 46

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

IS - 1

ER -